Bicara Therapeutics (BCAX) Competitors $14.37 -0.51 (-3.43%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. OGN, CPRX, VKTX, XENE, MLTX, ALVO, IMVT, HCM, ACAD, and APLSShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Immunovant (IMVT), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics Alvotech Immunovant HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Organon & Co. (NYSE:OGN) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do analysts prefer OGN or BCAX? Organon & Co. presently has a consensus target price of $19.75, indicating a potential upside of 52.63%. Bicara Therapeutics has a consensus target price of $32.43, indicating a potential upside of 125.68%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33Bicara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the MarketBeat Community prefer OGN or BCAX? Organon & Co. received 4 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Bicara Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes1833.33% Underperform Votes3666.67% Bicara TherapeuticsOutperform Votes1487.50% Underperform Votes212.50% Does the media favor OGN or BCAX? In the previous week, Organon & Co. had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for Organon & Co. and 9 mentions for Bicara Therapeutics. Organon & Co.'s average media sentiment score of 1.06 beat Bicara Therapeutics' score of 1.02 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Bicara Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, OGN or BCAX? Organon & Co. has higher revenue and earnings than Bicara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.40B0.53$864M$3.333.89Bicara TherapeuticsN/AN/AN/AN/AN/A Do insiders & institutionals have more ownership in OGN or BCAX? 77.4% of Organon & Co. shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is OGN or BCAX more profitable? Organon & Co. has a net margin of 13.49% compared to Bicara Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 431.62% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Bicara Therapeutics N/A N/A N/A SummaryOrganon & Co. beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$783.50M$6.89B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.21%P/E RatioN/A7.4422.4418.48Price / SalesN/A242.73394.10103.59Price / CashN/A65.8538.1834.62Price / BookN/A6.516.774.25Net IncomeN/A$143.21M$3.22B$248.23M7 Day Performance-7.35%3.95%3.25%3.29%1 Month Performance7.24%0.34%0.01%2.42%1 Year PerformanceN/A2.58%18.00%5.54% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara TherapeuticsN/A$14.37-3.4%$32.43+125.7%N/A$783.50MN/A0.0032Analyst RevisionNews CoveragePositive NewsGap DownOGNOrganon & Co.4.7679 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Upcoming EarningsPositive NewsCPRXCatalyst Pharmaceuticals4.6879 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4756 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals2.5984 of 5 stars$34.70-1.2%$56.78+63.6%-6.0%$2.66B$9.43M-12.30210Positive NewsMLTXMoonLake Immunotherapeutics1.553 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsALVOAlvotech1.7832 of 5 stars$8.33+0.5%$18.00+116.1%-45.9%$2.51B$489.68M-4.504Short Interest ↑IMVTImmunovant2.0477 of 5 stars$14.46-4.6%$41.00+183.5%-41.1%$2.46BN/A-5.52120High Trading VolumeHCMHUTCHMED1.9455 of 5 stars$13.89+0.9%$19.00+36.8%-19.8%$2.42B$630.20M0.001,760Short Interest ↑ACADACADIA Pharmaceuticals4.2577 of 5 stars$14.38-2.4%$23.93+66.4%-12.6%$2.40B$957.80M18.44510Upcoming EarningsAnalyst ForecastAPLSApellis Pharmaceuticals4.1083 of 5 stars$18.03-0.9%$45.35+151.5%-56.5%$2.26B$781.37M-8.88770Upcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies OGN Competitors CPRX Competitors VKTX Competitors XENE Competitors MLTX Competitors ALVO Competitors IMVT Competitors HCM Competitors ACAD Competitors APLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAX Stock Free BCAX Stock Alerts